This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D82.2 (immunodeficiency with short-limbed stature) | OMIM: 250250 (CHH) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Cartilage-hair hypoplasia (CHH), McKusick-Cross syndrome, immunodeficiency with brachydactyly, Metaphyseal chondrodysplasia McKusick type, immunodeficiency with short-limbed stature |
| C. Adult onset | Likelihood of first onset in adulthood low — abnormal bone development and dwarfism are evident at birth, while clinical manifestations of immunodeficiency appear across childhood to adolescence; in adults as well, there are cases first diagnosed with complicating malignancy (lymphoma, etc.) or a mild immunodeficiency phenotype. |
| 1. History | 1965, first described by McKusick in the Amish community → triad of short limbs, fine hair and immunodeficiency → identification of the RMRP gene (2001) → high-frequency founder effect confirmed in Finnish and Amish populations … and others. |
| 2. Causes | Autosomal recessive; RMRP gene (9p13.3) variants → dysfunction of the small nuclear RNA for mitochondrial RNA processing → multiple impairments of cell cycle regulation, cartilage development and immune function. |
| 3. Genetics | RMRP gene, non-coding RNA; 9p13.3. Diverse variant types (point mutations, insertions/deletions). Finnish founder variant (g.71A>G). High phenotypic heterogeneity — correlation between phenotype and genotype incomplete. |
| 4. General epidemiology | Finland 1:23,000; Amish 1:1,300. Rare worldwide. Rare in Korea. Malignancy risk increased 6–9-fold compared with the general population. |
| 5. Pathophysiology | RMRP RNA has roles in mitochondrial RNA cleavage and rRNA processing → reduced chondrocyte proliferation → epiphyseal growth plate abnormalities → brachydactyly. At the same time, impaired T-cell proliferation, reduced NK cells and defective antibody production. |
| 6. Symptoms | Disproportionate dwarfism (short limbs), fine sparse hair, recurrent viral infections (severe varicella), skin abnormalities, spinal stenosis, possible accompanying Hirschsprung disease, malignancies (non-Hodgkin lymphoma, basal cell carcinoma). |
| 7. Signs | Height <150cm, short and bowed limbs; X-ray: irregular growth plates, epiphyseal widening; lymphopenia, reduced T cells (CD4+); serum IgG/A/M normal to low; red cell macrocytosis; possible hemolytic anemia. |
| 8. Screening | Newborns with a family history: RMRP gene testing + imaging (skeletal abnormalities). Immune screening: T-cell fraction, TREC. Finnish and Amish high-risk populations: targeted testing for founder variants. |
| 9. Diagnosis | Skeletal X-ray (findings of metaphyseal chondrodysplasia), RMRP gene sequencing, T/B/NK cell fractions (flow cytometry), lymphocyte function tests, serum immunoglobulins, with whole-exome analysis in parallel. |
| 10. Treatment | Curative: hematopoietic stem cell transplantation (HSCT; indicated for severe immunodeficiency or lymphoma). Supportive: IVIG, prophylactic anti-infectives, live varicella vaccine contraindicated → VZIG prophylaxis after exposure. Growth hormone has limited efficacy. |
| 11. Prognosis | Normal lifespan possible without immunodeficiency. Poor prognosis with severe immunodeficiency or lymphoma. Successful immune reconstitution after HSCT reduces infection-related deaths. Continuous monitoring for malignancy risk needed. |
| 12. Prevention | Genetic counseling, preimplantation and prenatal genetic testing; live vaccines contraindicated; VZIG after varicella exposure; regular malignancy screening; prevention of orthopedic complications. |
| 13. References | McKusick VA et al. Dwarfism in the Amish … and 9 other papers |
The history of cartilage-hair hypoplasia (CHH) began in 1965 when the American geneticist Victor A. McKusick systematically described a unique cluster of dwarfism in the Amish community of Pennsylvania. In a paper published in the Bulletin of the Johns Hopkins Hospital, McKusick and his colleagues first defined, under the name 'cartilage-hair hypoplasia', a syndrome seen in Amish children characterized by dwarfism with disproportionately short limbs, sparse fine hair and immune abnormalities. The report at the time focused mainly on the specificity of the skeletal dysplasia, but also noted that high susceptibility to serious infections was observed in some patients.
Through the 1970s and 1980s, the immune abnormalities in patients with CHH began to be characterized in more detail. Several research groups systematically reported reduced T-lymphocyte numbers and function, reduced natural killer cells (NK cells) and, in some patients, reduced antibody function. In particular, a considerable number of patients with similar traits were also found in Finland, revealing that CHH is not confined to the Amish community but is an international disease also associated with a Finnish founder effect. Finnish epidemiologic studies confirmed that the prevalence of the disease is 1 per 23,000 population, lower than in the Amish population (1 per 1,300) but very high compared with the general population.
The molecular genetic cause of CHH reached a landmark turning point in 2001 when a Finnish research team including Marjana Törmäinen-Heinonen identified RMRP (RNA component of mitochondrial RNA-processing endoribonuclease) as the causative gene. The RMRP gene is a non-coding RNA gene that does not encode a protein, and it drew attention as a rare example of a non-coding RNA gene variant causing a complex multisystem disease. This discovery brought fundamental changes to the pathophysiology, diagnosis and genetic counseling of CHH, and it was later revealed that the spectrum of RMRP variants spans not only CHH but the entire spectrum of anauxetic dysplasia and metaphyseal chondrodysplasia McKusick type.
Since the 2000s, the risk of CHH-related malignancy has been quantified through large cohort studies. The Finnish CHH registry study (Mäkitie et al.) reported that the risk of non-Hodgkin lymphoma, basal cell carcinoma and others in patients with CHH is increased about 6–9-fold compared with the general population. Along with this, single-center and multicenter reports have accumulated showing that hematopoietic stem cell transplantation (HSCT) is effective for CHH with severe immunodeficiency and related lymphoma. CHH is currently classified as ICD-10 D82.2, and as a complex multisystem rare genetic disease combining skeletal dysplasia and immunodeficiency, a multidisciplinary approach spanning internal medicine, orthopedics, immunology and others is emphasized.
The cause of CHH is pathogenic variants of the RMRP gene. The RMRP gene is located on the short arm of chromosome 9 (9p13.3) and is a short non-coding RNA gene consisting of a single exon. The RMRP RNA it encodes functions in the cell as the RNA component of two key ribonucleoprotein complexes. First, in the mitochondria, it acts as a component of the RNase MRP complex involved in processing mitochondrial RNA (mtRNA), which is essential for mitochondrial DNA replication; second, in the nucleus, it plays an essential role in cleavage of precursor ribosomal RNA (pre-rRNA).
When an RMRP variant occurs, the RNA component of the RNase MRP complex is functionally impaired, resulting in multiple cellular dysfunctions such as ① abnormal mitochondrial RNA processing, ② impaired precursor rRNA cleavage → reduced ribosome production and ③ abnormal cell cycle regulation (reduced degradation of cyclin B2 mRNA → abnormal entry into the G2/M phase). These multifaceted dysfunctions explain why CHH shows abnormalities across various systems, including skeletal development, immune function and predisposition to malignancy.
CHH follows an autosomal recessive mode of inheritance. When both parents are carriers, an affected child is born with a 25% probability in each pregnancy. Reported RMRP variant types include point mutations (variants in the 5' transcribed region around the transcription start site being the most common), small insertions or deletions and, more rarely, large structural rearrangements. The most common founder variant in Finnish patients is an A→G substitution at the 71st nucleotide from the transcription start of the gene (g.71A>G), and a separate founder variant has also been identified in Amish patients.
Phenotypic heterogeneity is very high, so that even among patients with the same RMRP genotype, the severity of immunodeficiency, the degree of skeletal abnormalities and whether malignancy develops differ markedly. This suggests that, besides RMRP gene variants, modifier genes or environmental factors are also involved in determining the phenotype. In genetic counseling, it is important to fully explain this uncertainty in phenotype prediction.
The causative gene of CHH, RMRP (RNA component of mitochondrial RNA-processing endoribonuclease), is located at 9p13.3 on the short arm of chromosome 9 and is registered in OMIM as #157660. The CHH disease itself is OMIM #250250. The RMRP gene is a non-coding RNA gene about 265 nucleotides long consisting of a single exon, and it is unusual as a causative gene of a rare genetic disease in that it does not encode a protein. The RMRP RNA produced by this gene acts as the RNA catalytic component of the RNase MRP (mitochondrial RNA processing) enzyme.
In the RMRP variant spectrum, point mutations account for the largest share; in particular, variants in the promoter region near the transcription start site are reported to be associated with severe phenotypes (SCID-like immunodeficiency or anauxetic dysplasia), whereas variants within the gene tend to be associated with relatively mild phenotypes (classic CHH). However, the genotype-phenotype correlation is incomplete, limiting accurate prognosis prediction.
As a founder variant in the Amish population, g.70A>G (or a similar position) is often cited, and in Finnish patients g.71A>G is the most common allele. The carrier frequency of this single variant in Finland is estimated at about 1%. Compound heterozygous variants are also found in many patients, and the phenotype may differ depending on the combination of the two variants. Targeted sequencing of the RMRP gene is recommended first over whole-exome sequencing (WES) or whole-genome sequencing (WGS) in terms of diagnostic efficiency, but when the causative variant is not identified, panel/WES testing is used complementarily.
Key points of genetic counseling include ① carrier parents are asymptomatic but are already at risk of having an affected child, ② the likelihood of an affected child in the next pregnancy is 25%, ③ preimplantation genetic testing (PGT) and prenatal diagnosis (CVS/amniocentesis) are both technically possible and ④ because phenotypic heterogeneity is high, it is difficult to predict the severity of the immune phenotype even after genetic confirmation. Confirmation of the genetic diagnosis is also essential for identifying parental carriers, assessing the risk to siblings and selecting a suitable HSCT donor (HLA testing).
CHH is rare worldwide but is characterized by high frequency in specific populations. The population with the highest prevalence is the North American Amish community, where a frequency of about 1 per 1,300 births has been reported. This is because the founding population of the Amish community consisted of a small number of founder ancestors, so the carrier frequency of specific RMRP founder variants is high. In Finland, a prevalence of about 1 per 23,000 births is reported, which is understood as part of the Finnish disease heritage. Sporadic cases are reported in Northern European countries other than Finland.
The incidence in the general Western population has not been precisely established but is estimated at less than 1 per 100,000–200,000. Epidemiologic data in Asian populations are limited, and occurrence in Korea is also very rare, with no separate domestic epidemiologic statistics published. In Korea, a very small number of patients are presumed to be registered under code D82.2 in the Health Insurance Review & Assessment Service (HIRA) rare disease Special Copayment Reduction (V111) registration records. Males and females are equally affected without sex difference (autosomal recessive inheritance).
A notable epidemiologic feature in patients with CHH is a marked increase in the risk of malignancy. In long-term follow-up studies of the Finnish CHH cohort, the standardized incidence ratio (SIR) of non-Hodgkin lymphoma was reported to be increased about 6–9-fold and that of basal cell carcinoma about 3–5-fold (Mäkitie et al., 2003, 2008). Because this malignancy risk accumulates with age, ongoing malignancy screening is needed in adult patients with CHH as well. The frequency of accompanying Hirschsprung disease is also higher than in the general population, reported in about 10–15% of patients with CHH.
Even among primary immunodeficiencies, because of its unique phenotype combined with skeletal dysplasia, management of CHH by medical staff with appropriate expertise is important, and a multidisciplinary approach including internal medicine (immunology), orthopedics (skeletal complications) and medical oncology (malignancy surveillance) is essential.
The pathophysiology of CHH is understood as complex cellular dysfunction stemming from the multifunctional roles of RMRP RNA. RMRP RNA is the RNA catalytic component of the RNase MRP enzyme, which ① in the nucleus, is involved in cleavage of precursor 18S rRNA (pre-rRNA), mediating ribosome production, ② in the mitochondria, is responsible for cleavage of RNA primers for mitochondrial DNA (mtDNA) replication and ③ is involved in degradation of cyclin B2 mRNA, a cell cycle regulator. When RMRP variants reduce the function of this enzyme, complex impairments occur in each pathway.
Abnormal skeletal development: normal ribosome production is essential for chondrocyte proliferation and differentiation. Reduced RMRP function → abnormal pre-rRNA cleavage → reduced ribosome production → reduced division capacity of chondrocytes → reduced cell numbers in the proliferative zone of the growth plate → delayed growth of the long bones of the limbs → formation of disproportionately short limbs (rhizomelic/mesomelic shortening). Abnormalities of the cartilage component are more prominent than those of bone tissue itself, so deformity of the epiphysis and growth plate irregularity appear as characteristic imaging findings.
Abnormal immune function: T lymphocytes require rapid proliferation upon activation, and sufficient ribosome production and protein synthesis capacity are essential for this proliferation. Defective ribosome production due to reduced RMRP function selectively limits the proliferative capacity of T cells, resulting in reduced T-cell numbers and function. NK cells are also reduced, and B-cell numbers are normal, but antibody function may be reduced due to lack of T-cell help. Abnormal cell cycle regulation (abnormal cyclin B2 degradation) is also proposed as an additional mechanism disrupting the normal proliferative cycle of immune cells. The severity of immunodeficiency varies greatly between patients, showing a broad spectrum from severe SCID-like T-cell deficiency to mild T-cell dysfunction.
Predisposition to malignancy: abnormal DNA replication and cell cycle regulation (reduced RMRP function → impaired cyclin B2 mRNA degradation → abnormal G2/M transition) cause sustained genomic instability, and combined with impaired T-cell and NK-cell immune surveillance, immune elimination of malignantly transformed cells is reduced. The synergy of these two pathways explains the high risk of lymphoma and basal cell carcinoma observed in CHH.
The clinical symptoms of CHH consist of multisystem abnormalities spanning the skeletal system, the immune system and other systems, and the severity of the phenotype varies greatly between patients.
Skeletal symptoms are the most characteristic. Disproportionate dwarfism is evident from birth, with limb shortening prominent relative to the trunk (disproportionate short stature). Final height is usually in the range of 100–150 cm. Short, thick and bowed limbs (especially the lower limbs), joint hypermobility, mild lumbar lordosis and scoliosis are observed. Spinal canal stenosis can develop in adults, causing radiating pain in the lower limbs, gait disturbance and voiding dysfunction. As hair abnormalities, the hair is very fine, sparse and light-colored, and the eyelashes and eyebrows are likewise sparse.
Immune symptoms have a broad spectrum. In mild cases, they amount to severe disease or complications with varicella infection and recurrent respiratory infections; in severe cases, serious opportunistic infections comparable to SCID (Pneumocystis pneumonia, disseminated candidiasis) can occur. In particular, high susceptibility to varicella-zoster virus (VZV) infection is clinically important, and disseminated varicella or VZV pneumonia can be life-threatening.
Other accompanying symptoms: as a gastrointestinal abnormality, Hirschsprung disease (accompanying in about 10–15%) presents as congenital megacolon, chronic constipation and bowel obstruction. Macrocytic anemia and hemolytic anemia are also observed. The risk of malignancy increases from adolescence onward; non-Hodgkin lymphoma (NHL) is the most common, and basal cell carcinoma of the skin is also increased. Hodgkin lymphoma has also been rarely reported.
The clinical signs of CHH are confirmed in various ways on physical examination and ancillary tests. On anthropometry, marked dwarfism with a final height of 100–150 cm is observed, and the limb-to-trunk ratio is lower than normal. The fingers are short and thick, and hypermobility of the wrist and ankle joints is confirmed. The hair is fine and sparse, with a soft texture.
Radiographic findings are central to diagnosis. X-rays of the long bones characteristically show findings of metaphyseal chondrodysplasia: irregular cup-shaped depression (cupping) of the diaphyseal-epiphyseal junction (metaphysis), growth plate widening and reticular irregularity of the epiphysis (scalloping). These findings are observed throughout the long bones of the limbs, and in the ribs irregularity of the costochondral junctions (similar to a rachitic rosary) is seen. Spine X-rays may show mild vertebral body irregularity, and in adults findings of spinal canal stenosis are confirmed on MRI.
Immunologic test findings: on peripheral blood flow cytometry, a reduced absolute lymphocyte count (ALC) and reduced CD4+ T cells are typical. CD8+ T cells are relatively preserved or reduced, and a low CD4/CD8 ratio is common. NK-cell (CD16+CD56+) numbers are also reduced. Serum immunoglobulins (IgG, IgA, IgM) vary from normal to low. Reduced responses are observed on T-cell proliferation testing (PHA stimulation). In severe patients, reduced TREC is confirmed. On complete blood count (CBC), macrocytic anemia (increased MCV), abnormal platelet counts and findings related to hemolytic anemia (positive direct Coombs test, elevated bilirubin) may appear.
When Hirschsprung disease is present: delayed passage of meconium and abdominal distension are observed in the neonatal period, and absence of ganglion cells is confirmed by barium enema or rectal suction biopsy.
Systematic newborn screening programs for CHH are not currently standardized in the general population, except in the Amish and Finnish high-risk populations. However, the following situation-specific screening approaches are recommended.
Newborns with a family history: if a parent or sibling has been confirmed as affected with CHH or as a carrier of an RMRP variant, targeted RMRP variant analysis is performed immediately after birth. At the same time as genetic confirmation, peripheral blood T/B/NK cell fractions (flow cytometry) and TREC quantification (dried blood spot or peripheral blood) are performed to assess for T-cell immunodeficiency. Skeletal abnormalities are confirmed by prenatal ultrasound (limb shortening observed at around 18–22 weeks of gestation) or by radiography after birth.
Amish and Finnish high-risk populations: targeted screening for each population's founder variant (Finland: g.71A>G; Amish: the corresponding founder variant) can be performed efficiently in newborns or as prenatal testing during pregnancy. In these populations, population-level genetic counseling and screening programs are clinically meaningful.
Infants with suspected T-cell deficiency: in countries that have introduced TREC-based newborn immune screening, the severe immunodeficiency phenotype of CHH can be detected as reduced TREC, which can lead to a diagnosis of CHH through follow-up confirmatory testing. A stepwise approach of abnormal TREC result → flow cytometry → RMRP gene testing is recommended.
Malignancy screening (adult and adolescent patients with CHH): regular malignancy screening after the diagnosis is confirmed is recommended as a preventive measure. This includes immediate work-up when symptoms suggestive of lymphoma such as lymphadenopathy, night sweats and weight loss occur, and an annual dermatologic examination for skin lesions (suspected basal cell carcinoma).
The diagnosis of CHH consists of 3 steps: ① confirmation of characteristic skeletal dysplasia findings, ② assessment of immune function and ③ confirmation of an RMRP gene variant.
Skeletal radiography: findings of metaphyseal chondrodysplasia are confirmed by X-rays of all the long bones of the limbs and the spine. The findings characteristic of the McKusick type are cup-shaped depression of the metaphysis, growth plate widening and epiphyseal irregularity, reflecting abnormalities in the normal calcification and ossification of cartilage. In children, widening of the costochondral junctions is also observed. In adults, the degree of spinal canal stenosis is assessed with spinal MRI.
Assessment of immune function: peripheral blood flow cytometry measures the absolute numbers and fractions of T cells (CD3+, CD4+, CD8+), B cells (CD19+) and NK cells (CD16+CD56+). TREC quantification indirectly assesses thymic activity. T-cell function testing (PHA-stimulated proliferative response) confirms the degree of T-cell dysfunction. Antibody function is assessed by quantification of serum immunoglobulins (IgG, IgA, IgM) and measurement of antigen-specific antibodies (antibody titers after vaccination). CBC checks for anemia and leukocyte abnormalities.
RMRP gene analysis: Sanger sequencing or NGS of the entire RMRP gene (including the promoter region) is performed to identify pathogenic variants. For those of Finnish or Amish descent, targeted testing for the founder variant is done first, and if negative, whole-gene sequencing is performed. The carrier status of the parents is checked to confirm the mode of inheritance.
Assessment for Hirschsprung disease: in newborns with constipation or symptoms of bowel obstruction, barium enema, anorectal manometry and rectal suction biopsy (to confirm absence of ganglion cells) are performed.
Differential diagnosis: differentiation is needed from other metaphyseal chondrodysplasias (metaphyseal chondrodysplasia Schmid type, Jansen type), anauxetic dysplasia (RMRP variant but more severe), vitamin D-deficient rickets (similar growth plate abnormalities), achondroplasia (FGFR3 variant) and Schwachman-Diamond syndrome (combination of immunodeficiency + skeletal abnormalities).
Treatment of CHH varies greatly depending on the severity of the immunodeficiency. In patients with mild immunodeficiency, treatment centers on supportive care, and in patients with confirmed severe T-cell deficiency, hematopoietic stem cell transplantation (HSCT) is considered.
Hematopoietic stem cell transplantation (HSCT): HSCT is indicated for severe T-cell deficiency, a history of life-threatening opportunistic infections or the development of CHH-related lymphoma. HSCT is the only curative approach that corrects the immunodeficiency component of CHH, and successful immune reconstitution and improved survival have been confirmed in reports from several institutions. HSCT does not correct the skeletal or hair abnormalities of CHH, but markedly reduces infection-related morbidity and mortality. For conditioning, reduced-intensity conditioning (RIC) is preferred in consideration of the patient's general condition and skeletal abnormalities.
Intravenous immunoglobulin (IVIG) replacement therapy: in patients with confirmed reduced antibody function, regular IVIG administration (every 3–4 weeks) is expected to prevent bacterial infections. Serum IgG is maintained at or above the target level (800–1000 mg/dL or higher).
Prophylactic anti-infective therapy: in patients with confirmed severe T-cell deficiency, TMP-SMX (Pneumocystis prophylaxis) and antifungals (candidiasis prophylaxis) are given prophylactically. The live varicella vaccine is absolutely contraindicated, and after VZV exposure, varicella-zoster immune globulin (VZIG) is given immediately or an antiviral (acyclovir) is used prophylactically. For transfusion, irradiated, CMV-negative blood products are used.
Management of skeletal complications: in cooperation with an orthopedic specialist, progression of spinal canal stenosis is assessed and joint abnormalities are managed. If severe spinal canal stenosis develops, surgical decompression may be necessary. Growth hormone (GH) has been tried for dwarfism in CHH, but its effect is limited and it could theoretically increase the risk of malignancy, so it is not routinely recommended.
Treatment and surveillance of malignancy: when lymphoma develops, standard chemotherapy or HSCT is combined, and basal cell carcinoma is treated dermatologically, such as by excision. From confirmation of the diagnosis, regular malignancy screening (monitoring of lymphadenopathy, skin lesions, LDH and blood count abnormalities) is carried out throughout life.
The prognosis of CHH is mainly determined by the severity of the immunodeficiency and whether malignancy develops. Patients with mild immunodeficiency, especially when T-cell numbers and function are only mildly reduced, can expect a normal or near-normal lifespan with appropriate infection prevention measures. However, patients with severe T-cell deficiency have a high risk of early death from recurrent infections without treatment.
Prognosis after HSCT: in patients with CHH with severe immunodeficiency, infection-related morbidity and mortality decrease markedly when immune reconstitution after HSCT is successful. Reports from several institutions have reported a 5-year survival of 70–85% after HSCT. The skeletal, hair and gastrointestinal abnormalities of CHH are not corrected by HSCT, so ongoing specialist care for them is needed.
Malignancy-related prognosis: when non-Hodgkin lymphoma develops, early detection and treatment are important for survival. Basal cell carcinoma can be cured by surgical treatment, but there is a risk of recurrence and multiple occurrences. Because the presence of malignancy is one of the factors with the greatest influence on the long-term prognosis of patients with CHH, systematic monitoring from diagnosis throughout life is important.
When Hirschsprung disease is present: with appropriate surgical management in the neonatal period, the long-term prognosis is good, but bowel dysfunction may persist. Overall, because CHH is a complex multisystem disease, a system in which a multidisciplinary care team spanning internal medicine (immunology/rare diseases), orthopedics, medical oncology/hematology-oncology, gastroenterology and dermatology cooperates throughout the patient's life is ideal.
Prevention of CHH is divided into prevention of disease occurrence (primary), prevention of complications (secondary) and suppression of the progression of long-term complications (tertiary).
Primary prevention: genetic counseling begins with identifying RMRP variant carriers and systematically explaining the risk of an affected child in the next pregnancy (25%). Preimplantation genetic testing (PGT) can be used to select unaffected embryos, or prenatal genetic diagnosis can be performed during pregnancy by chorionic villus sampling (CVS, 11–14 weeks) or amniocentesis (15–20 weeks). If limb shortening is observed on prenatal ultrasound after 18–22 weeks of gestation, RMRP gene testing is also recommended.
Secondary prevention: after the diagnosis is confirmed, prophylactic anti-infective therapy is given according to the degree of immunodeficiency. The live varicella vaccine and other live vaccines are absolutely contraindicated, and caution is also required in using live vaccines such as oral polio vaccine and varicella vaccine in siblings and household members. After VZV exposure, VZIG or acyclovir is given immediately. In patients with severe immunodeficiency, use of TMP-SMX (Pneumocystis prophylaxis), IVIG and irradiated blood products is standard. Determining the indication for HSCT early and performing transplantation before infectious complications occur improves prognosis.
Tertiary prevention: from diagnosis throughout life, regular malignancy screening (lymph node palpation, skin examination, LDH, complete blood count and, if needed, PET-CT) is performed. Surveillance of spinal canal stenosis progression (MRI) and early orthopedic intervention prevent neurologic complications. Patients with accompanying Hirschsprung disease need long-term management of bowel function and monitoring of nutritional status. Psychosocial support for the family and linkage to rare disease patient networks are also included.
McKusick VA, Eldridge R, Hostetler JA, Egeland JA, Ruangwit U. Dwarfism in the Amish. II. Cartilage-hair hypoplasia. Bulletin of the Johns Hopkins Hospital. 1965;116:285–326. PMID: 14284412.
Ridanpää M, van Eenennaam H, Pelin K, et al. Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell. 2001;104(2):195–203. DOI: 10.1016/S0092-8674(01)00205-7. PMID: 11207361.
Mäkitie O, Kaitila I. Cartilage-hair hypoplasia—clinical manifestations in 108 Finnish patients. European Journal of Pediatrics. 1993;152(3):211–217. DOI: 10.1007/BF01956147. PMID: 8444213.
Mäkitie O, Marttinen E, Kaitila I. Skeletal muscle in cartilage-hair hypoplasia. Histomorphometric study. Acta Neuropathologica. 1997;94(2):139–144. PMID: 9255390.
Mäkitie O, Pukkala E, Teppo L, Kaitila I. Increased incidence of cancer in patients with cartilage-hair hypoplasia. Journal of Pediatrics. 1999;134(3):315–318. DOI: 10.1016/S0022-3476(99)70457-1. PMID: 10064672.
Kavadas FD, Giliani S, Gu Y, et al. Variability of clinical and laboratory features among patients with ribonuclease mitochondrial RNA processing endoribonuclease gene mutations. Journal of Allergy and Clinical Immunology. 2008;122(6):1178–1184. DOI: 10.1016/j.jaci.2008.09.040. PMID: 19022486.
Taskinen M, Ranki A, Pukkala E, Jeskanen L, Kaitila I, Mäkitie O. Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma. American Journal of Medical Genetics Part A. 2008;146A(18):2370–2375. DOI: 10.1002/ajmg.a.32478. PMID: 18698618.
Notarangelo LD, Fleisher TA. Immunodeficiency associated with skeletal dysplasias. In: Stiehm ER, Ochs HD, Winkelstein JA, eds. Immunologic Disorders in Infants and Children. 5th ed. Elsevier Saunders; 2004:499–514.
Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology. 2018;38(1):96–128. DOI: 10.1007/s10875-017-0464-9. PMID: 29226301.
Bertuch AA. The molecular genetics of the telomere biology disorders. RNA Biology. 2016;13(8):696–706. DOI: 10.1080/15476286.2016.1185803. PMID: 27149507.